Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2009

01-01-2009 | Gastrointestinal Oncology

Perioperative Chemotherapy for Gastric Cancer

Authors: E. Fatourou, MD, A. Macheras, MD, E. P. Misiakos, MD, T. Liakakos, MD

Published in: Annals of Surgical Oncology | Issue 1/2009

Login to get access

Excerpt

Persiani et al. report on perioperative chemotherapy for gastric cancer in a most recent issue of Annals of Surgical Oncology.1 Although this is a small, nonrandomized study, careful selection of patients with locally advanced gastric cancer (LAGC) for perioperative chemotherapy merits our comments considering the current debate on optimal adjuvant treatment. …
Literature
1.
Persiani R, Rausei S, Pozzo C, et al. 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study. Ann Surg Oncol 2008 Jun 10. [Epub ahead of print]
2.
Liakakos T, Roukos DH. More controversy than ever-challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 2008;15:956–60CrossRefPubMedPubMedCentral
3.
Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 2006; 6:931–9CrossRefPubMed
4.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20CrossRefPubMed
5.
Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; 14:2691–5CrossRefPubMed
6.
Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357:1810–20CrossRefPubMed
7.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinomas of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725–30CrossRefPubMed
8.
Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002; 9:220–1CrossRefPubMed
9.
Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12CrossRefPubMed
10.
Roukos DH, Ziogas D. Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 2008 Jul 9. [Epub ahead of print]. DOI: 10.​1245/​s10434-008-0056-2
11.
Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 2008; 26(26):4360–4361CrossRefPubMed
12.
Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873–9CrossRefPubMedPubMedCentral
13.
Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007; 4:578–90CrossRefPubMed
14.
15.
Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007; 357:1555–6; author reply 1556CrossRefPubMed
16.
Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 2008; 15:21–33CrossRefPubMed
17.
Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4CrossRefPubMed
18.
19.
Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998;123:573–8CrossRefPubMed
20.
Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999; 6:46–56CrossRefPubMed
21.
Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003; 10:718–21CrossRefPubMed
22.
Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5:737–45CrossRefPubMed
23.
Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2008; 358:197, author reply 198
24.
Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med 2008 10;358:1636; author reply 1636
25.
Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 2008; 8:29–39CrossRefPubMed
26.
Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 2008; 8(5):587–597CrossRefPubMed
27.
Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 2008. DOI: 10.​1245/​s10434-008-0190-6
Metadata
Title
Perioperative Chemotherapy for Gastric Cancer
Authors
E. Fatourou, MD
A. Macheras, MD
E. P. Misiakos, MD
T. Liakakos, MD
Publication date
01-01-2009
Publisher
Springer New York
Published in
Annals of Surgical Oncology / Issue 1/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0117-6

Other articles of this Issue 1/2009

Annals of Surgical Oncology 1/2009 Go to the issue

Thoracic Oncology

Improving Outcomes with Lung Cancer Surgery: Selective Referral or Quality Improvement?

Erratum

Erratum to Laparoscopic-Assisted Versus Open Abdominoperineal Resection for Low Rectal Cancer: A Prospective Randomized Trial

Hepatobiliary and Pancreatic Tumors

Expression and Clinical Significance of Cell Cycle Regulatory Proteins in Gallbladder and Extrahepatic Bile Duct Cancer

Laboratory and Translational Research

Tissue Microarray Analysis of 560 Patients with Colorectal Adenocarcinoma: High Expression of HuR Predicts Poor Survival

Healthcare Policy and Outcomes

Validation of the Mexican Spanish Version of the EORTC C30 and STO22 Questionnaires for the Evaluation of Health-Related Quality of Life in Patients with Gastric Cancer

Gastrointestinal Oncology

Prognostic Significance of the Number of Metastatic Lymph Nodes: Is UICC/TNM Node Classification Perfectly Suitable for Early Gastric Cancer?